Multiple Sclerosis

The AJMC® Multiple Sclerosis compendium is a comprehensive resource for clinical news and expert insights for the disabling disease that impacts the brain and spinal cord.

Latest News

Ocrelizumab and hyaluronidase is now the first and only twice-yearly subcutaneous injection approved for RMS and PPMS. | Image Credit: BHM - stock.adobe.com
Subcutaneous Ocrelizumab and Hyaluronidase Approved for RMS, PPMS

September 17th 2024

Ocrelizumab and hyaluronidase is now the first and only twice-yearly subcutaneous injection approved for relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS).

The eSDMT was developed to facilitate more frequent cognitive assessments for people with multiple sclerosis. | Image credit: fizkes - stock.adobe.com
Remote Test Reliably Assesses Cognitive Function in MS

September 12th 2024

The new results make HERCULES the first and only study to demonstrate reduced CDP in nrSPMS. | Image credit: Juan Gärtner - stock-adobe.com
Tolebrutinib Delays Disability Progression in Nonrelapsing Secondary Progressive MS

September 3rd 2024

AJMC Q&A with JT Lew, PharmD, MBA | Background image credit: ipopba - stock.adobe.com
Dr JT Lew Explores the Barriers to MS Medication Access

September 3rd 2024

Doctor examining MRI images - New Africa - stock.adobe.com
Stable MRI in Multiple Sclerosis Reveals Relapses as Acute Clinical Events

August 21st 2024

Examining the Role of a Novel Class of Medications for the Management of Multiple Sclerosis

This video series provides an in-depth look at multiple sclerosis, covering its impact, pathophysiology, treatment strategies, unmet needs, patient satisfaction, and future research. Gain key insights into managing and understanding this condition.

This video series provides an in-depth look at multiple sclerosis, covering its impact, pathophysiology, treatment strategies, unmet needs, patient satisfaction, and future research. Gain valuable insights into managing and understanding this complex condition.
Continuing Medical Education
View All
September 19th 2024

New and Emerging Treatment Strategies for Myasthenia Gravis: The Role of the Specialty Pharmacist

1.0 Credit / Neurology
September 19th 2024

Improving Treatment Access for Spinal Muscular Atrophy: How Managed Care Strategies Can Ease Clinical and Caregiver Burden

1.5 Credits / Neurology
September 19th 2024

Assessing the Treatment Landscape for Multiple Sclerosis to Better Individualize Care

1.5 Credits / Neurology
September 19th 2024

Exploring Transthyretin-Mediated Amyloidosis and Its Phenotypes: A Comprehensive Approach to Patient Treatment

1.5 Credits / Cardiology, Neurology, Rare Diseases
September 19th 2024

The Economics of Transthyretin-Mediated Amyloidosis: Balancing Equity and Access in Resource Allocation

1 Credit / Cardiology, Neurology
September 19th 2024

Advancing Targeted Therapies Aimed at Smoldering Disease in Multiple Sclerosis

1.0 Credit / Immunology, Neurology
September 19th 2024

The Role of the Specialty Pharmacist in Optimizing Treatment for Amyotrophic Lateral Sclerosis: The Impact of Early Intervention, Patient-Centered Care, and Disease-Modifying Therapies in Slowing Disease Progression

1.0 Credit / Neurology

More News

Graphic of brain and spinal cord
May 29th 2021

Study Tracks Social Cognition, Amygdala Changes in Patients With RRMS

Jared Kaltwasser
Patient social cognition remained stable over 3 years, but its correlation with structural damage in the brain changed over time.
MS-affected nerve graphic
May 27th 2021

MS Wrap-up: World MS Day, Practice Effects on MSPT Battery, and More

Maggie L. Shaw
Here are some of the latest developments in multiple sclerosis (MS) from our sister publication, NeurologyLive®.
Study: Confirmed Disability Progression Provides Limited Predictive Value in MS
May 21st 2021

Study: Confirmed Disability Progression Provides Limited Predictive Value in MS

Jared Kaltwasser
Confirmed disability progression is often used as a study endpoint to predict progression, but a new report says its predictive value may be overblown.
Neon graphic of brain
May 19th 2021

MS Wrap-up: Research Needs in Progressive MS, AAN Annual Meeting, and More

Maggie L. Shaw
Here are some of the latest developments in multiple sclerosis (MS) from our sister publication, NeurologyLive®.
brain graphic
May 15th 2021

Study Identifies Potential Molecular Biomarker of Progressive MS

Gianna Melillo
Using data from 2 independent cohorts, researchers identified a potential molecular biomarker for progressive multiple sclerosis (MS).
Strength exercise
May 13th 2021

Metabolic Changes May Indicate Improved Clinical Outcomes in Multiple Sclerosis

Progressive resistance training was shown to positively alter several measures of disease progression in the study cohort: fatty acid, phospholipid, and sex steroid metabolism.
Teen with MS
May 7th 2021

Recent Gains for Patients With POMS Linked to Therapeutic, Disease Management Advancements

Maggie L. Shaw
Although knowledge is plentiful on disease state improvements for adult patients with multiple sclerosis (MS) following use of newer disease-modifying therapies, less is known about similar outcomes among patients with pediatric-onset MS (POMS).
Antibodies in bloodstream
May 3rd 2021

B-Cell Depletion May Indicate Reduced COVID-19 Antibody Response Among Patients With MS

Maggie L. Shaw
New research demonstrates that patients with multiple sclerosis (MS) who were asymptomatic for COVID-19 had lower antibody levels against SARS-CoV-2, its causative virus, due to having fewer B cells.
Informational chart
April 30th 2021

DMT Uptake, Prescriptions Not Fitting Disease Course Among Patients With MS

Maggie L. Shaw
Because real-world data are lacking on disease-modifying treatment (DMT) prescribing patterns for patients with multiple sclerosis (MS), a team of investigators wanted to make sure these individuals were receiving adequate care.
Tracking patients
April 26th 2021

MS Care Not So Routine During the Pandemic

Maggie L. Shaw
Risk of infection topped the list of concerns among patients with multiple sclerosis (MS) who altered their usual care routines during the COVID-19 pandemic.
SARS-CoV-2 graphic
April 21st 2021

MS Patients on Ocrelizumab May Have Lessened Immune Response to SARS-CoV-2

Maggie L. Shaw
In an abstract presented at this year’s American Academy of Neurology annual meeting, patients with multiple sclerosis (MS) taking ocrelizumab had less of an immune reaction to infection with SARS-CoV-2, the virus that causes COVID-19.
Forschung
April 19th 2021

DMT Alone Not a Good Predictor of COVID-19 Among Patients With MS

Maggie L. Shaw
Compared with disease-modifying therapy (DMT), age, insurance status, and Hispanic ethnicity were shown to more accurately predict likelihood of COVID-19 and hospitalization from it among individuals with multiple sclerosis (MS).
health technology graphic
April 16th 2021

DMD Decision Aid Tool for Patients With MS Runs Into Efficacy Challenges

Gianna Melillo
An online tool developed to facilitate efficient patient-provider decisions on disease modifying drugs for multiple sclerosis (MS) ran into several challenges and warrants further study.
Female researcher
April 13th 2021

Clinical Surveillance Remains Necessary Among Cladribine-Treated Patients With RRMS

Maggie L. Shaw
A prospective bicentric cohort study among individuals with relapsing-remitting multiple sclerosis (RRMS) showed that 32% developed at least 1 skin-related adverse reaction following cladribine administration.
Image of fatigued person
April 10th 2021

Understanding the Patient Factors Linked to Fatigue in Multiple Sclerosis

Maggie L. Shaw
The advent of both new diagnostic criteria and treatments have necessitated a reevaluation of fatigue among individuals who have multiple sclerosis, investigators say.
Stack of books to be read
April 7th 2021

Review Explores Health Literacy in Patients With MS

Christina Mattina
Because health literacy can have different meanings for patients with different diseases, this review aimed to crystalize a definition in patients with multiple sclerosis (MS) and emphasize its importance in care planning.
Pill bottles
April 1st 2021

Infection Risk May Increase With Fingolimod Use in Patients With MS

Maggie L. Shaw
Among patients with multiple sclerosis, there is a 16% greater risk of infection, including for lower respiratory and herpes virus infections, after administration of fingolimod.
Neon neuron
March 30th 2021

Transcranial Direct Current Stimulation May Benefit Patients With MS

Maggie L. Shaw
With most current therapies for patients with multiple sclerosis (MS) targeting disease progression, a recent review evaluated transcranial direct current stimulation’s ability to improve certain disease symptoms.
Brain in gear
March 26th 2021

Researchers Identify 4 Distinct Phenotypes of Cognitive Impairment in MS

Maggie L. Shaw
Investigators aimed to close the knowledge gap on interindividual variability in cognitive evaluation outcomes by considering both cognitive impairment and mood disorders to better prediction accuracy.
Spoonfuls of supplements
March 24th 2021

Review Recommends Guidelines for Patients With MS Taking Herbal Drugs, Supplements

Maggie L. Shaw
With many patients with multiple sclerosis (MS) increasingly turning to herbal drugs and supplements to treat their disease, for which there is no cure, a recent review evaluated the safety of these alternative therapies.
Sick women
March 19th 2021

Risk Factors Identified That Predispose Patients With MS, COVID-19 to Worse Outcomes

Maggie L. Shaw
Among these factors, having a higher degree of disability from multiple sclerosis (MS) was independently associated with higher morbidity and mortality risks from having a comorbid case of COVID-19.
Various patient measurements
March 17th 2021

Infection Risk, Medical Claims High Among Patients With Multiple Sclerosis

Maggie L. Shaw
Patients with multiple sclerosis have high rates of urinary and kidney infections, inpatient hospitalizations, and outpatient hospital claims, according to recent results presented at the Americas Committee for Treatment and Research in Multiple Sclerosis annual meeting.
Money for medicine
March 10th 2021

Medicare Part D Payments for MS Medications Outpace Inflation

Maggie L. Shaw
Investigators sought to better understand increasing price trends, including those seen among disease-modifying drugs to treat multiple sclerosis (MS) and other neurological diseases.
Warming group of people
March 5th 2021

Study Investigates Link Between Multiple Sclerosis, Warmer Weather

Maggie L. Shaw
Preliminary study results point to a possible connection between increasing global temperatures and an increased risk of hospitalization during the course of multiple sclerosis (MS).
Highlighted outline of a person's mind
March 2nd 2021

Mixed Improvements Seen Among Patients With MS Practicing Mindfulness

Maggie L. Shaw
A systematic review and meta-analysis of studies of patients with multiple sclerosis (MS) found that mindfulness- and acceptance-based interventions did not have a significant effect on mindfulness among these patients.
Group of happy kids
February 26th 2021

Researchers Highlight Need for Pediatric-Specific Treatment, Research for MS

Maggie L. Shaw
Compared with adult-onset multiple sclerosis (MS), pediatric-onset MS has few treatments directed at the condition, specifically those that promote remyelination, enhance neuroprotection, and remediate cognitive deficits.
research results
February 24th 2021

Amiselimod Most Effective S1P Receptor Modulator for Patients With MS

Maggie L. Shaw
Among 6 sphingosine-1-phosphate (S1P) receptor modulators evaluated for use in patients with multiple sclerosis (MS), a new meta-analysis shows amiselimod had the highest efficacy.
Progressive MS Alliance Seeks Change to Study Designs to Spur New Therapies
February 20th 2021

Progressive MS Alliance Seeks Change to Study Designs to Spur New Therapies

Skylar Jeremias
Advocates for patients with progressive multiple sclerosis (MS) want changes in study designs on emerging therapies to speed development and better align with the needs of researchers and patients.
Close-up of syringe and vial
February 19th 2021

MS Society Releases Guidance on DMT Dosing Modifications for COVID-19 Vaccination

Jaime Rosenberg
The current guidance emphasizes that the mRNA-based Pfizer/BioNTech and Moderna vaccines are safe for people with multiple sclerosis (MS) taking disease modifying therapies (DMTs).
Dr Burcu Zeydan Explains How Aging Impacts Multiple Sclerosis
February 12th 2021

Dr Burcu Zeydan Explains How Aging Impacts Multiple Sclerosis

Timing of relapses in multiple sclerosis is one of several interactions among aging, the trajectory of progressive disease, and worsening disability, according to Burcu Zeydan, MD, assistant professor of neurology, assistant professor of radiology, at the Mayo Clinic.
<123456789
...
20>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2024 MJH Life Sciences® and AJMC®.
All rights reserved.

Über uns
Kontakt
Editorial Boards
Advertise
Do Not Sell My Information
Allgemeine Geschäftsbedingungen
Datenschutzbestimmungen
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo